logo
episode-header-image
Jul 2021
35m 24s

Novel Lipid-Lowering Therapies to Reduce...

JAMA NETWORK
About this episode

Several new therapeutic drug classes are now available to manage lipid levels. John Wilkins, MD, MS, and Donald Lloyd-Jones, MD, ScM, of the Department of Preventive Medicine and Division of Cardiology at Northwestern University Feinberg School of Medicine, discuss the use of ezetimibe, PCSK-9 inhibitors, bempedoic acid, and icosapent ethyl to manage lipid levels in patients taking statins who require additional LDL lowering.

Related Content:

Up next
Mar 19
Update on Peanut Allergy
Peanut allergy affects about 2% of people in the US and most commonly develops in early childhood. Peanut introduction during infancy has led to decreased prevalence of peanut allergy. Author Elissa Abrams, MD, MPH, of the University of Manitoba joins JAMA Deputy Editor Kristin W ... Show More
18m 32s
Mar 9
Obesity-Related Cancer
Overweight and obesity may cause 10% of new cancer diagnoses annually in the US. In this JAMA Review in the Translational Science series, author Neil Iyengar, MD, of Emory University discusses the biological pathways that may promote cancer in people with overweight or obesity an ... Show More
21m 21s
Mar 2
Diagnosis and Treatment of Chronic, Noninfectious Diarrhea
Chronic noninfectious diarrhea affects approximately 6% to 7% of adults in the US and significantly impairs quality of life. Author William Chey, MD, of the University of Michigan joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss strategies for diagnosis and treatment of ... Show More
19m 55s
Recommended Episodes
Jul 2019
LDL-Senkung 4.0
Die Statintherapie gilt als einer der größten Fortschritte in der Prävention atherosklerotisch bedingter kardiovaskulärer Ereignisse. Doch trotz Statingabe erreichen viele Patienten nicht ihre Ziel-LDL-Werte. Bempedoic Acid (kurz BA) könnte für diese Patienten ein potenter Kombin ... Show More
8m 59s
May 2022
207. Lipids: REDUCE-IT Versus STRENGTH Trials – EPA in Clinical Practice with Dr. Peter Toth
CardioNerds Tommy Das (Program Director of the CardioNerds Academy and cardiology fellow at Cleveland Clinic), Rick Ferraro (cardiology fellow at the Johns Hopkins Hospital), and Dr. Aliza Hussain (cardiology fellow at Baylor College Medicine) take a deep dive on the REDUCE-IT tr ... Show More
53m 59s
Sep 2021
143. Lipids: (Non)-Fasting LDL & Furious Lipid Lowering with Dr. Alison Bailey
CardioNerds Dr. Rick Ferraro, Director of the #CardsJC Journal Club and cardiology fellow at Johns Hopkins, and Dr. Tommy Das, Program Director of the CardioNerds Academy and cardiology fellow at Cleveland Clinic, learn all about the clinical application of the ASCVD primary and ... Show More
35m 49s
Jun 2024
#525: Cholesterol-Lowering Medication – Dr. Paddy Barrett
<p>Cholesterol-lowering medications, particularly statins, play a pivotal role in reducing low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) concentrations, which are causal markers in atherosclerosis development. The efficacy of these medications is well-do ... Show More
48m 29s
Sep 2023
When Hyperkalemia Impairs Optimal Treatment of HF and CKD: What New Guidelines Recommend
<p>Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF).<br />   <br /> Credit available for ... Show More
31m 24s
May 2023
#255 ‒ Latest therapeutics in CVD, APOE's role in Alzheimer's disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
tail spinning
2h 4m
Nov 2023
Nurturing young minds and beyond: The Omega-3 connection
Acting Department Chair and Canada Research Chair in Brain Lipid Metabolism. Dr. Bazinet and his team are currently taking a kinetic and biochemical approach to studying the mechanisms by which dietary polyunsaturated fatty acids regulate the metabolism of arachidonic and docosah ... Show More
39m 17s
Jun 2021
Glipizide Pharmacology
Glipizide, or Glucotrol, is a sulfonylurea used for the treatment of Type 2 Diabetes. Pharmacologically, glipizide acts by stimulating beta-cells in the pancreas to release insulin. Specifically, glipizide will block the opening of ATP-sensitive potassium channels on the plasma m ... Show More
12m 46s